Damaged String Biosciences appoints Laurence Reid and Brad Crutchfield to its Board of Administrators

Damaged String Biosciences (“Damaged String”), a genomics firm enabling the event of the following technology of extra exact, secure, and efficient cell and gene therapies, as we speak introduced the appointments of Laurence Reid, PhD, as Chairman, and Brad Crutchfield as Non-Government Director (NED) of its Board of Administrators.

Bringing in depth industrial and management experience to the Board, Laurence and Brad will play a pivotal position in offering strategic oversight as Damaged String prepares for its subsequent part of economic development. Working carefully with CEO Felix Dobbs, PhD, they may assist advance the corporate’s INDUCE-seq® product providing to deal with the numerous unmet wants of its world buyer base inside the increasing cell and gene remedy market.

Laurence is a seasoned biotech entrepreneur with a monitor file of management and company-building success inside the sector. He was beforehand CEO of Decibel Therapeutics (acquired by Regeneron Prescribed drugs) and Warp Drive Bio (merged with Revolution Medicines). He served as an entrepreneur in residence at Third Rock Ventures, targeted on novel drug discovery and improvement alternatives.

Previous to this, he held C-level government positions at Alnylam Prescribed drugs, Ensemble Discovery, and Millennium Prescribed drugs. Laurence now applies his experience in an advisory capability, serving on the boards of a number of biotech firms. He’s additionally a board member at The Potential Zone and an advisor to Life Science Cares and Mount Auburn Hospital.

Brad brings practically 40 years of expertise within the improvement and commercialization of life science instruments to Damaged String’s Board. Most just lately, he served as Chief Industrial Officer of 10x Genomics, constructing the worldwide gross sales and assist group that as we speak drives over $600 million in enterprise and dealing carefully with the CEO to assist the Firm by way of its IPO in 2019.

Beforehand, Brad held a number of management positions, together with senior vp of life sciences at QIAGEN, vp and common supervisor of EMEA at Illumina, and president of the life science group at Bio-Rad Laboratories. He presently sits on the Boards of Pixelgen AB, Partillion Inc., and S2 Genomics and serves as Senior Advisor for Alamar Biosciences.

“Laurence and Brad convey distinguished careers and a robust historical past of driving impression and development inside our business. It’s a privilege to welcome them to the Damaged String crew,” mentioned Felix Dobbs, PhD, CEO of Damaged String Biosciences. “As we push ahead with our bold development technique and work to attain our industrial targets, their experience can be instrumental in shaping our strategic route.“

“The promise of therapies primarily based on genome enhancing is essentially linked to understanding the specified genome modifications relative to the undesired modifications. INDUCE-seq is an especially promising expertise that can allow therapeutic builders to convey their cutting-edge remedies to market with a brand new normal of precision. I’m happy to be becoming a member of the Firm and desirous to work carefully with the management crew to develop a complete industrial technique and assist the Firm in its ongoing development.”

Laurence Reid, PhD, Chair of the Board, Damaged String Biosciences

“Cell and gene therapies maintain immense promise for remodeling illness therapy, and Damaged String’s answer can be instrumental in serving to firms speed up and de-risk their drug improvement pipelines. By enabling the event of those next-generation therapies with precision and security, we will improve enterprise worth for pharma and biotech corporations. I stay up for leveraging my expertise in bringing progressive life science instruments to market to assist place the corporate’s choices for achievement on this quickly evolving discipline.”

​​​​​​​Brad Crutchfield, Non-Government Director at Damaged String Biosciences